| Period | EPS (Actual vs Estimate) | Revenue (Actual vs Estimate) | Surprise |
|---|---|---|---|
| Q3 2025 | –$0.11 vs –$0.18 | $334.2 M vs $328.7 M | Beat on both lines |
Bullish: First profitability print and continued 80 % growth.
Neutral: Guide raise underwhelming relative to expectations.
Bearish: GAAP losses and SBC still heavy.
Tempus delivered on growth and profitability proof points but did not expand its forward profit guide enough to satisfy a valuation-rich AI healthcare tape, explaining the post-print sell-off.
Conference call is up next for more color from management.
First positive Adj. EBITDA (+$1.5 M) — proof of operating discipline.
Gross margin expansion to 63.6 %, up 400 bps YoY.
GAAP loss from operations widened to –$61 M from –$53 M YoY due to Ambry amortization and Paige acquisition costs.
Guidance raise modest ($1.26 B → $1.265 B).
Stock-based compensation up ~$34 M, keeping total opex elevated.
Paige acquisition adds AI pathology capability but creates temporary margin drag.
Management guided Q4 Adjusted EBITDA to ~$20 M, offset by $5 M/quarter Paige losses, implying a modestly profitable full year, a solid but not transformative step-up.
| Metric | Prior FY 2025 Guide | New FY 2025 Guide | Direction |
|---|---|---|---|
| Revenue | $1.26 B | $1.265 B | Raised slightly |
| Adj. EBITDA | +$5 M | +$10 M (≈ flat post-Paige acq.) | Raised |
| FY 2026 Revenue View | $1.56 B | Reiterated | Flat |
“Not only are we growing at an incredible rate, reaching positive adjusted EBITDA marks an important milestone and reflects the strength of our underlying business,” said Founder & CEO Eric Lefkofsky. “One of the hardest things to do … is slow the rate of reinvestment and still maintain growth, which is exactly what we achieved.”
Lefkofsky emphasized scalability and discipline, but investors wanted stronger forward EBITDA visibility after an aggressive reinvestment cycle.
Shares down over 7% after the first take.
Revenue was $334.21 million, above the $332.02 million consensus estimate. EPS was -$0.46, below the -$0.17 consensus estimate. Tempus AI, Inc. reported a significant year-over-year revenue growth of 84.7% for Q3 2025, reaching $334.2 million, driven by strong performance in genomics and data services. Gross profit improved by 98.4% to $209.9 million, although the company reported a net loss of $80 million, slightly higher than the $75.8 million loss in Q3 2024.
The company achieved a positive adjusted EBITDA of $1.5 million, marking a substantial improvement from the previous year’s negative $21.8 million. Tempus increased its full-year revenue guidance to $1.265 billion, reflecting an 80% growth year-over-year. The company ended the quarter with $764.3 million in cash and marketable securities.
Live coverage has ended. The full story is below.
Tempus AI (NASDAQ: TEM | TEM Price Prediction) reports third-quarter results after the close, and investor attention is turning toward how the company will follow up on its breakout second quarter. The precision medicine and data analytics firm has become one of the most closely watched names in AI-driven healthcare, and its recent performance shows why.
In Q2, Tempus delivered revenue of $314.6 million, up nearly 90% year over year, and a normalized EPS loss of $0.22, beating estimates by three cents. Genomics revenue surged 115% as oncology testing volumes jumped 26% and hereditary testing climbed 32%, while Data and Insights revenue grew nearly 36% to about $73 million. Management raised its full-year 2025 revenue guidance to $1.26 billion and reaffirmed its forecast for positive $5 million in adjusted EBITDA, an improvement of more than $100 million from last year.
CEO Eric Lefkofsky said the company is “hitting its stride” approaching its tenth anniversary, noting that Tempus is balancing rapid top-line growth with disciplined investment. Its issuance of $750 million in low-interest convertible notes also strengthened liquidity, leaving the firm well-capitalized as it scales its AI initiatives.
Here’s what Wall Street expects when Tempus reports:
| Period | Revenue | EPS (Normalized) | YoY Revenue Growth |
|---|---|---|---|
| Q3 2025 (Current Qtr) | $328.67M | –$0.18 | +81.7% |
| Q4 2025 (Next Qtr) | $360.06M | –$0.10 | +79.4% |
| FY 2025 | $1.26B | –$0.72 | +81.6% |
| FY 2026 | $1.56B | –$0.12 | +24.1% |
Tempus has now exceeded EPS expectations in three of the past four quarters, with an average positive surprise of about 9%. Analysts expect continued sequential improvement in margins and a potential inflection toward breakeven by early 2026.
1. AI Foundation Model Expansion
Tempus’ multi-year partnership with AstraZeneca and Pathos to train a large-scale biomedical foundation model is a central narrative. Management said it is running compute across 1,000 H200 GPUs on over 350 petabytes of data — a scale that could reshape how pharma companies identify responders to therapies. Investors will look for signs that additional pharma partners are lining up to participate.
2. Genomics Growth and Market Share Gains
Q2 genomic testing volumes surged across oncology and hereditary lines, aided by improved salesforce efficiency and technology upgrades. The hereditary segment’s market share gains, particularly through the Ambry platform, have been a key driver, and management called growth “durable and sustainable” into Q3.
3. Path Toward Profitability
Adjusted EBITDA losses narrowed sharply to $5.6 million in Q2 from –$16 million in Q1. The company reaffirmed full-year profitability guidance, citing disciplined cost control and operational leverage. With revenue growing north of 30% at scale, investors will be watching if the margin expansion continues.
4. MRD and Liquid Biopsy Catalysts
Tempus expects reimbursement for its minimal residual disease (MRD) assays by late 2025, positioning this franchise for meaningful 2026 growth. The liquid biopsy and treatment response monitoring pipeline could add incremental volume once payers approve coverage.
5. Data and Insights Momentum
Following 40% growth in Q2, management guided for approximately 30% full-year growth in its Data and Insights business. This segment, fueled by large pharma partnerships, is key to Tempus’ long-term AI monetization strategy.
Contact [email protected] for any questions or corrections.
Joel South covers large-cap stocks, dividend investing, and major market trends, with a focus on earnings analysis, valuation, and turning complex data into actionable insights for investors.
He brings more than 15 years of experience as an investor and financial journalist, including 12 years at The Motley Fool, where he served as an investment analyst, Bureau Chief, and later led the Fool.com investing news desk. He has also co-hosted an investing podcast and appeared across TV and radio discussing market trends.
Tempus AI (NASDAQ: TEM | TEM Price Prediction) reports full Q4 2025 and full-year results after the market closes, with the market already holding a preliminary revenue figure. The real question tonight is what…
Tempus AI (NASDAQ:TEM) reported Q1 2026 revenue of $348.1 million, up 36.1% year-over-year, beating estimates while MRD volumes surged roughly 500% year-over-year to approximately 6,500 tests. The stock that burst into investor consciousness after…
Tempus AI (NASDAQ: TEM | PLTR Price Prediction), a fast-rising player in clinical AI and health data infrastructure, will report its Q1 2025 earnings after the market closes today. Analysts expect revenue of $248.1…
Tempus AI wrote a $1.5 billion check for a genomics company most investors had never heard of, and one blockbuster clinical trial announcement just changed everything about how that deal looks.
Yesterday investors watched to see whether Tempus AI’s full-year and Q4 2025 results would validate the profitability story that the January pre-announcement left unfinished. The complete financials are now in, and this morning shares…
Most asset managers try to track the market. Through ARK Investment, Cathie Wood is trying to get ahead of the market’s best ideas by identifying disruptive innovation early, even when the underlying businesses are…
Shares of Nancy Pelosi’s favorite artificial intelligence stock Tempus AI (NASDAQ:TEM | TEM Price Prediction) are falling more than 13% in morning trading after reporting fourth quarter and full-year 2024 earnings results yesterday after…
It’s been a rocky few days for Tempus AI (NASDAQ:TEM | TEM Price Prediction). After hitting a high of $91.45, the stock plummeted to a low of $55.20. All thanks to an earnings miss…
Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one has climbed…
